Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3899908 | 0.95 | DNM1 (0.36) | DNM1ALDH1A1TDP1TSHRCA2 | |
| SCHEMBL1582227 | 0.95 | DNM1 (0.42) | DNM1TSHRCA2LMNAFDPS | |
| SCHEMBL4261190 | 0.92 | DNM1 (0.46) | DNM1TSHRCA2LMNAFDPS | |
| SCHEMBL2347365 | 0.92 | DNM1 (0.46) | DNM1TSHRCA2LMNAFDPS | |
| SCHEMBL18007368 | 0.92 | OPRM1 (0.42) | DNM1TSHRLMNAFDPSOPRM1 | |
| SCHEMBL4263383 | 0.89 | — | — | |
| SCHEMBL4263651 | 0.89 | LMNA (0.42) | DNM1TSHRLMNAFDPSOPRM1 | |
| SCHEMBL4274138 | 0.85 | LMNA (0.39) | DNM1TSHRLMNAFDPSOPRM1 | |
| SCHEMBL3891523 | 0.81 | — | — | |
| SCHEMBL7799148 | 0.81 | OPRM1 (0.39) | DNM1TSHRLMNAFDPSOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1472227-B1 | PROCESS FOR THE MANUFACTURE OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2016-04-27 | — | — | EP | claimed |
| EP-2298745-B1 | PREPARATION METHOD OF ROSUVASTATIN CALCIUM AND ITS INTERMEDIATES | CHANGZHOU PHARMACEUTICAL FACTORY (CN) | 2014-09-03 | — | — | EP | claimed |
| US-20090299065-A1 | PROCESS FOR THE MANUFACTURE OF ORGANIC COMPOUNDS | CHEN GUANG-PEI | 2009-12-03 | — | — | US | claimed |
| US-7572917-B2 | Process for the manufacture of organic compounds | NOVARTIS AG (CH) | 2009-08-11 | — | — | US | claimed |
| US-6835838-B2 | Condensation of silicon compounds with aldehydes in the presence of titanium catalysts in solvents, then reducing and hydolyzing to form drugs used for prophylaxis of atherosclerosis or as enzyme inhibitors | NOVARTIS AG (CH) | 2004-12-28 | — | — | US | claimed |
| US-20040249154-A1 | Process for the manufacture of organic compounds | CHEN GUANG-PEI (US) | 2004-12-09 | — | — | US | claimed |
| EP-1472227-A2 | PROCESS FOR THE MANUFACTURE OF ORGANIC COMPOUNDS | Novartis AG (CH) | 2004-11-03 | — | — | EP | claimed |
| US-20030208072-A1 | Process for the manufacture of organic compounds | NOVARTIS AG (CH) | 2003-11-06 | — | — | US | claimed |
| WO-2003064382-A2 | PROCESS FOR THE MANUFACTURE OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2003-08-07 | — | — | WO | claimed |
| EP-1472227-B1 | PROCESS FOR THE MANUFACTURE OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| EP-1375485-B1 | METHOD FOR PREPARING 7-QUINOLINYL-3,5-DIHYDROXYHEPT-6-ENOATE | NISSAN CHEMICAL IND LTD (JP) | 2011-04-20 | — | — | EP | disclosed |
| US-20100228028-A1 | PROCESSES FOR THE MANUFACTURE OF ROSUVASTATIN AND INTERMEDIATES | ASTRAZENECA UK LIMITED (GB) | 2010-09-09 | — | — | US | disclosed |
| US-20090299065-A1 | PROCESS FOR THE MANUFACTURE OF ORGANIC COMPOUNDS | CHEN GUANG-PEI | 2009-12-03 | — | — | US | disclosed |
| EP-2091923-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN | AstraZeneca UK Limited (GB) | 2009-08-26 | — | — | EP | disclosed |
| EP-0519496-A1 | Thermosetting copolymers, silicon carbide-based fiber and processes for producing same | Tonen Corporation (JP) | 1992-12-23 | — | — | EP | disclosed |
| US-5128286-A | BORON-CONTAINING, SILICON NITRIDE-BASED CERAMIC SHAPED BODY | TONEN CORPORATION (JP) | 1992-07-07 | — | — | US | disclosed |
| EP-0475627-A1 | Optically active esters of 7-substituted 3,5-difunctionalized 6-heptenoic acids | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1992-03-18 | — | — | EP | disclosed |
| US-5030744-A | Polyborosilazane and process for producing same | TONEN CORPORATION (JP) | 1991-07-09 | — | — | US | disclosed |
| EP-0404503-A1 | Boron-containing, silicon nitride-based ceramic shaped body production process | Tonen Corporation (JP) | 1990-12-27 | — | — | EP | disclosed |
| EP-0389084-A2 | Process for producing a polyborosilazane | Tonen Corporation (JP) | 1990-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228028-A1 | PROCESSES FOR THE MANUFACTURE OF ROSUVASTATIN AND INTERMEDIATES | HMGCR, PCSK9, CYP4A11 | DNM1 1992/4885ALDH1A1 284/4885TDP1 4474/4885 |
| US-20090299065-A1 | PROCESS FOR THE MANUFACTURE OF ORGANIC COMPOUNDS | HSD11B1, HSD3B1, HSD11B2 | DNM1 2253/4885ALDH1A1 223/4885TDP1 1256/4885 |
| US-20040249154-A1 | Process for the manufacture of organic compounds | HSD11B1, HSD3B1, HSD11B2 | DNM1 2253/4885ALDH1A1 223/4885TDP1 1256/4885 |
| US-20030208072-A1 | Process for the manufacture of organic compounds | HSD11B1, HSD3B1, HSD11B2 | DNM1 2253/4885ALDH1A1 223/4885TDP1 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.